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Introduction and Background 
The older population of the United States is in a period of rapid growth [1]. The 
population of those in the United States aged 65 or older will double to about 72 million 
in the next 25 year [1]. This population is at increased risk for obesity, chronic diseases, 
decreased quality of life, and premature death. Therefore, guidelines for healthy aging are 
desperately needed. In 2015 alone, 67.7% of adults in the United States aged 65 or older 
reported having two or more chronic conditions [2]. Treatment for those in the older 
population afflicted by multiple chronic conditions alone accounts for 66% of the United 
States’ total health care budget [1]. In 2018, for the third year in a row, Arkansas was one 
of nine states with an adult obesity rate at or above 35 percent [3]. The obesity prevalence 
in Arkansans 65 years of age and older was reported to be 30.1% for 2018 and is 
projected to continue with an increasingly upward trajectory. In the United States, 
Arkansas was identified as having the 4th highest-ranked state with regard to overweight 
and obesity percentiles for adults. Arkansas was also identified as the 4th highest-ranked 
state for number of adults diagnosed with type 2 diabetes mellitus (T2DM). Additionally, 
in Arkansas alone 23.4% of adults aged 65 years of age or older were currently diagnosed 
with T2DM in 2015, with an expected increase in this percentage [2]. Poor sleep has been 
identified as one potential cause for this dramatic decline in health [4].  
Sleep disorders are highly prevalent in older adults with 50% or more older adults 
being currently diagnosed with a clinical sleeping disorder [5]. A lack of sleep schedule 
regularity in addition to poor sleep quality puts older adults at significantly higher risk for 
cognitive and functional decline [5]. Sleep loss in older adults has been specifically 
linked to an increased risk of T2DM and obesity [4]. While aging is linked to a general 
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decline in total sleep time and sleep efficiency, sleep efficiency has been shown to 
significantly decrease past age 60 [6].  
Adequate nutrition has the potential to combat dysregulated sleep and mood. 
Preference for fat-based dietary patterns have also been linked to poor sleep quality [7]. 
Those with poor quality sleep have been shown to typically select their diet from a 
smaller range of food groups, with low protein intake being cited as a common factor [7].  
Omega-3 fatty acid (O3FA) supplementation has been shown to prevent cognitive 
impairments, in both the long- and short-term, that arise from chronic sleep deprivation 
[8]. Additionally, a shift in dietary intake away from O3FAs toward saturated fats in 
Western countries, such as in the United States, has been linked to the rise in depression 
and other neurological disorders [9]. In conjunction with this linkage, O3FAs have 
demonstrated potential use in an antidepressant role [9]. 
Nutrition is a key factor in the prevention of muscle loss and body fat gain often 
observed with age [10,11]. Diets high in O3FAs have been linked to healthy aging [10]. 
Increasing consumption of O3FAs has shown decreased risk of cardiovascular disease 
and potential sleep quality improvement through a decrease in overall body fat. In 
addition, high protein diets have also been linked to healthy aging through decreasing 
body fat and increasing muscle mass [11]. Protein needs increase as individuals age, and 
the impairments on physical function from a lack of protein is most obvious in older 
adults [11]. The synergistic effects of protein and O3FA supplementation on sleep 
quality, mood, and body composition are currently unknown. 
For this study, measures to evaluate healthy aging will include weight, Body Mass 
Index (BMI), waist circumference measurements, and waist-to-hip ratios. BMI and waist 
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circumference measurements are both recognized as important measures of obesity and 
weight-related health risks [12]. Health risks increase as BMI increases, but within the 
obesity category (BMI ≥ 30) the National Institutes of Health (NIH) recognizes a graded 
scale at each obese category based upon waist circumference [12]. A higher waist 
circumference is associated with more health risks within a given BMI category. 
Specifically, a waist circumference >102cm for men or >88cm for women is considered a 
high waist circumference by the NIH [12]. Just as poor sleep is related to obesity and 
other chronic illnesses, obesity appears to also contribute to shorter sleep duration in a 
vicious cycle. Studies in adults have shown a significant decline in hours of sleep as BMI 
rises [13].  
The effects of aging are experienced greatly in a specific demographic—post 
menopausal women [14,15,16,17]. Postmenopausal women have been found to present 
larger waist circumferences and larger waist-to-hip ratios than premenopausal women in 
studies [14]. Gain of abdominal fat during menopause for postmenopausal women has 
also been shown to display statistical significance even after adjustment for age and total 
body fat mass when compared to premenopausal women [15]. At the core of complaints 
given among those who are postmenopausal is sleep disturbance [16]. Mood disturbance 
among postmenopausal women is also exacerbated beyond that found with aging alone. 
Women are twice as likely as men to be afflicted by depressive symptoms and disorders, 
and this risk is heightened upon reaching the transition toward becoming postmenopausal 
[17].  
The objective of this project was to determine whether increasing protein and 
O3FAs in the diet of aging postmenopausal women for 16 weeks would improve sleep 
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and overall well-being. We hypothesized that increased consumption of both protein and 
O3FAs would promote healthier aging in postmenopausal women through improved 
quality of sleep, reduced body weight, improved body composition, and improved mood. 
Signs of healthier aging would be shown through improved health measures—sleep 
quality, weight, BMI, waist-to-hip ratios, and overall mood. The demographic selected 
for this study was chosen as to negate the hormonal influence as well as to provide data 
on a population with little available research. 
 
Materials and Methods 
Subject Recruitment and Participation 
Prior to subject recruitment, the study was submitted to the University of 
Arkansas’ Institutional Review Board for approval and was registered on 
clinicaltrials.gov, clinical trial number: NCT0303041. Subjects were recruited on a 
voluntary basis through advertisement in the University of Arkansas Newswire, social 
media, and local businesses. In order to participate in the study, subjects were required to 
be postmenopausal women with a last reported menstrual cycle of 12 months or more 
prior, be absent of hormone replacement therapy (HRT), have no known food allergies, 
regularly eat breakfast, consume fatty fish 4 times or less per month, not taking 
medications that impact appetite, blood coagulation, metabolism, or blood lipids, not 
consuming protein or O3FA related supplements, and have an initial Pittsburgh Sleep 
Quality Index (PSQI) of 5 or greater, as this score indicated dysregulated sleep. All 
subjects completed a brief screening and filled out a consent form prior to enrolling in the 
study. Participants were recruited on a rolling basis and randomly assigned a treatment 




A total of 40 participants were recruited to partake in this 16-week randomized, 
single-blind, controlled study. Six participants dropped out of the study at various stages 
for different reasons—study visits were time-consuming to attend in the morning or they 
did not want to consume all necessary supplements. Thirty-four participants were 
randomly assigned to a control group or one of four treatment groups: 1) control—no 
supplements given, 2) 25 grams of whey protein, 3) 4.3 grams of omega-3 fatty acid 
supplements, 4) 25 grams of whey protein and 4.3 grams of soybean oil placebo 
supplements, or 5) 25 grams of whey protein and 4.3 grams of O3FAs supplements. 
Protein was consumed prior to 10:00 am, and the O3FA or placebo supplements were 
consumed in a 2.15 gram dose before 10:00 am as well as with the evening meal. Waist-
to-hip ratio measurements, height, weight, Pittsburgh Sleep Quality Index (PSQI) 
questionnaire results, and Profile of Mood States questionnaire results were recorded at 
the baseline, week 4, week 8, week 12, and week 16 visits. All five laboratory visits 
required fasting the night before (10-12h), as the blood samples were drawn by a certified 
phlebotomist to assess sleep and metabolic blood markers. In addition, sleep was assessed 
at baseline, 8 weeks, and 16 weeks. 
Educational Materials  
Participants were given a booklet that corresponded to their randomly assigned 
groups’ dietary intervention. All booklets included a standard study day schedule and 
checklist, as well as instructions for the sleep ActiGraph sleep monitors and sleep diary. 
Each booklet included a breakfast recipe section that was to be modified to incorporate 




Height, weight, and waist circumference, and hip circumference were measured at 
the baseline, week 4, week 8, week 12, and week 16 visits. Body height was measured to 
the nearest 0.01 cm using a stadiometer (Detecto, St. Louis, MO) while participants were 
barefoot, in the free-standing position. Body weight of participants was measured in the 
fasting state without shoes to the nearest 0.01 kg using calibrated balance scales (Detecto, 
St. Louis, MO). Body mass index (BMI) was calculated as weight (kg) divided by height 
(m) squared. Waist measurements were taken using the belly button as the standard 
position of the waist for each participant using a soft tape measure, and rounding to the 
nearest 0.1 cm. Hip measurements were taken at the widest point below the waist using 
the aforementioned soft tap measure, and rounding to the nearest 0.1 cm. Waist-to-hip 
ratios were recorded by dividing the waist measurement (cm) by the hip measurement 
(cm).  
Sleep Assessment 
Sleep quality was determined via wrist actigraphy. Wrist actigraphy utilizing the 
Cole-Kripke algorithm has been validated with high sensitivity, moderate specificity and 
high accuracy when compared to polysomnography, the current gold standard [18]. Each 
participant was required to wear an ActiGraph monitor on the non-dominant wrist for 7 
days during the month of the intervention. Wrist actigraphy was utilized the 7 days prior 
to the baseline, week 8, and week 16 visits. 60Hz was utilized as the sample rate, as this 
rate has been verified for sleep quality analysis. In addition to wearing the ActiGraph 
monitor, participants also filled out a 7-day sleep diary to accompany the data collection 
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via wrist actigraphy. Sleep times were verified and corrected by comparing the sleep 
diaries against the raw data downloaded.  
The Pittsburgh Sleep Quality Index (PSQI) questionnaire was utilized to measure 
subjective sleep quality. The PSQI questionnaire has high consistency and validity [19]. 
The PSQI questionnaire has also been specifically validated for use in older women of 
multiple ethnic groups [20]. The PSQI questionnaire was administered during all five 
visits—baseline, week 4, week 8, week 12, and week 16. 
Mood 
Mood was measured through administration of the commonly used Profile of 
Mood States (POMS) questionnaire [21]. The POMS questionnaire has been specifically 
validated and shown internal consistency in measuring mood in postmenopausal women 
[21]. The POMS questionnaire was administered at baseline, week 4, week 8, week 12, 
and week 16. Participants defined their mood on a 5-point Likert scale. The POMS 
questionnaire provided a score for Total Mood Disturbance (TMD), Anger-Hostility 
(Anger), Confusion-Bewilderment (Confusion), Depression-Dejection (Depression), 
Fatigue-Inertia (Fatigue), Tension-Anxiety (Tension), and Vigor-Activity (Vigor). For 
the Vigor measure a higher score, or a numerical increase in value after score comparison 
over time signifies an improvement in mood.  For Total Mood Disturbance (TMD), 
Anger, Confusion, Depression, Fatigue, and Tension a lower score, or a numerical 
decrease in value upon comparing scores over time signified an improvement in mood. 
TMD was calculated using the following equation: TMD = (Tension-Anxiety) + 
(Depression-Dejection) + (Anger-Hostility) + (Fatigue-Inertia) + (Confusion-
Bewilderment) – (Vigor-Activity). 
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Statistical Analysis  
One-way repeated measures analysis of variance (ANOVA) was used to assess 
the differences in BMI, waist-to-hip ratio, Global PSQI Scores, wrist actigraphy, and 
POMS scores between the five treatments over the course of the 16-week intervention. 
One-way ANOVA was used to look at the total change from baseline compared to the 
end of the 16-week intervention for Global PSQI scores and POMS TMD scores. Clinical 
biomarker differences were determined using repeated-measures ANOVA. A p-value < 
0.05 indicates statistical significance. Prism GraphPad Software Version 8.0 (La Jolla, 




A total of 34 participants completed the study. Table 1 shows the baseline 
characteristics of the participants in the study including: age, height, weight, body mass 
index (BMI), waist-to-hip ratio, global PSQI score, and total mood disturbance POMS 










Anthropometrics: BMI, Waist Circumference, and Waist-to-Hip Ratio Measurements  
 The calculated BMI, waist circumference, and waist-to-hip ratio measurements 
taken at each visit were compiled. The average of each per group was determined for 
each of the listed measures, and the results were standardized as change from baseline. 
 The line graph in Figure 1A shows the average BMI for each of the five 
treatment groups over the course of the study after controlling for baseline. A one-way 
repeated measures ANOVA did not result in any statistical significance. The bar graph in 
Figure 1B shows the average change in BMI from baseline at week 16 for each of the 
five treatment groups. A one-way ANOVA did not demonstrate any significance.  
The line graph in Figure 2A displays the average waist-to-hip ratio for each of the 
five treatment groups for each visit after controlling for baseline. A one-way repeated 
measures ANOVA demonstrated a significant difference (p < 0.05) between treatment 
groups. The bar graph in Figure 2B shows the average change in BMI  from baseline at 
week 16 for each of the five treatment groups. A one-way ANOVA did not demonstrate 
any significance, although the general trend for all treatment groups, and not the control 
group, to decrease in waist-to-hip ratios from baseline to week 16.  The Figure 2C 
displays the average waist circumference measurement for each of the five treatment 
groups after controlling for baseline. A one-way repeated measures ANOVA 
demonstrated a significant difference (p < 0.05) between treatment groups. All groups, 
except for the control group, tended toward a smaller waist circumference at the end of 






Figure 1. (A) The average BMI for each of the five treatment groups calculated for all 
five visits after controlling for baseline. No significance was found. (B) The average 
change in BMI from baseline at week 16 for each of the five treatment groups. No 





Figure 2.  
Figure 2. (A) The average waist-to-hip ratio for each of the five treatment groups 
calculated for all five visits after controlling for baseline. Significance was found 
between treatment groups (p < 0.05). (B) The average change in waist-to-hip ratio from 
baseline at week 16 for each of the five treatment groups. No significance was found. (C) 
The average waist circumference measurement for each of the five treatment groups 
calculated for all five visits after controlling for baseline. Significance was found 







Sleep quality was assessed by utilizing both The Pittsburgh Sleep Quality Index 
questionnaire (PSQI), as well as wrist actigraphy, during the course of the study.  
Sleep: The Pittsburgh Sleep Quality Index (PSQI) 
The PSQI Global Scores taken at the beginning of each participants’ visit were 
calculated and recorded with the scores of the other participants in their respective 
treatment groups. The average PSQI Global Scores for each of the five treatment groups 
was calculated for each visit. The line graph in Figure 3A shows the average PSQI 
Global Score for each of the five treatments groups for each visit after controlling for 
baseline A one-way repeated measures ANOVA demonstrated a strong significant effect 
(p < 0.0001) over time. The bar graph in Figure 3B shows the average change in PSQI 
score from baseline to week 16 for each of the five treatment groups. A one-way 
ANOVA demonstrated significant differences (p < 0.01) between treatments groups, 





Figure 3. (A) The Global PSQI Score average for each of the five treatment groups 
calculated for all five visits after controlling for baseline. Significance was found for time 
(p < 0.0001). (B) The average change in Global PSQI score from baseline at week 16 for 
each of the five treatment groups. Significance was found for treatment, between the 
O3FA and the Protein + O3FA groups (p < 0.01). Omega-3 fatty acids, O3FA; Pittsburgh 




Sleep: Wrist Actigraphy 
 The ActiGraph monitors were collected from each participant at the beginning of 
the baseline, week 8, and week 16 visits along with the corresponding sleep diary. Wrist 
actigraphy data was downloaded and analyzed using ActiLife v6.13.4 software 
(Pensacola, FL). Sleep times were verified and corrected by comparing the sleep diaries 
against the raw data downloaded. The sleep data was then analyzed to find total sleep 
time, total minutes in bed, sleep efficiency, number of awakenings, and length of 
awakenings.  
The line graph in Figure 4A displays the average Sleep Efficiency (total sleep 
time divided by time in bed) as a percentage, for each treatment group after controlling 
for baseline sleep efficiency. A one-way repeated measures ANOVA did not demonstrate 
significance. The line graph in Figure 4B displays the average Total Sleep Time in 
minutes for each treatment group after controlling for baseline. A one-way repeated 
measures ANOVA did not demonstrate significance. The line graph in Figure 4C 
displays the average Total Time in Bed in minutes for each treatment group after 
controlling for baseline. A one-way repeated measures ANOVA did not demonstrate 
significance. Figure 5A shows a line graph depicting the average Number of 
Awakenings for each group after controlling for baseline. A one-way ANOVA 
demonstrated significance for time (p < 0.05), as well as between treatments (p < 0.05). 
Figure 5B shows a line graph depicting the average Wake after Sleep Onset in minutes 
for each group after controlling for baseline. A one-way ANOVA demonstrated 





Figure 4. (A) The average Sleep Efficiency for each of the five treatment groups 
calculated for all five visits after controlling for baseline. No significance was found. (B) 
The average Total Sleep Time for each of the five treatment groups calculated for all five 
visits after controlling for baseline. No significance was found. (C) The average Time in 
bed for each of the five treatment groups calculated for all five visits after controlling for 







Figure 5. (A) The average Number of Awakenings for each of the five treatment groups 
calculated for all five visits after controlling for baseline. Significance was found for both 
time (p < 0.05), as well as between treatment groups (p < 0.05). (B) The average Number 
of Awakenings for each of the five treatment groups calculated for all five visits after 
controlling for baseline. Significance was found for both time (p < 0.05), as well as 





Mood: Profile of Mood States Questionnaire (POMS) 
 The POMS questionnaires filled out at the beginning of each participants’ visit 
were recorded and compiled to produce a score for each of the following: Total Mood 
Disturbance (TMD), Anger, Confusion, Depression, Fatigue, Tension and Vigor. These 
scores were recorded with those of the other participants in their respective treatment 
groups. The average POMS score for each of the five treatment groups was calculated per 
mood distinction category for each visit. 
The line graph Figure 6A shows the average TMD score for each of the five 
treatments groups for each visit after controlling for baseline. A one-way repeated 
measures ANOVA did not demonstrate significance. The bar graph in Figure 6B shows 
the average change in TMD score from baseline at week 16 for each of the five treatment 
groups. A one-way ANOVA demonstrated no significance. 
 Figure 7A displays the average Anger score for each of the five treatments 
groups for each visit after controlling for baseline. A one-way repeated measures 
ANOVA did not demonstrate significance. Figure 7B displays the average Confusion 
score for each of the five treatments groups for each visit after controlling for baseline. A 
one-way repeated measures ANOVA demonstrated significance (p < 0.05) between 
treatment groups. Figure 7C displays the average Depression score for each of the five 
treatments groups for each visit after controlling for baseline. A one-way repeated 
measures ANOVA did not demonstrate significance. Figure 7D displays the average 
Fatigue score for each of the five treatments groups for each visit after controlling for 
baseline. A one-way repeated measures ANOVA did not demonstrate significance 
Figure 7E displays the average Tension score for each of the five treatments groups for 
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each visit after controlling for baseline. A one-way repeated measures ANOVA 
demonstrated significance (p < 0.05) between groups. Figure 7F displays the average 
Vigor score for each of the five treatments groups for each visit after controlling for 
baseline. A one-way repeated measures ANOVA demonstrated significance (p < 0.05) 





Figure 6. (A) The average TMD score for each of the five treatments groups for each 
visit after controlling for baseline. No significance was found. (B) The average change in 
TMD score from baseline at week 16 for each of the five treatment groups. No 






Figure 7. (A) The average Anger score for each of the five treatments groups for each 
visit after controlling for baseline. No significance was found. (B) The average Confusion 
score for each of the five treatments groups for each visit after controlling for baseline. 
Significance was found between treatment groups (p < 0.05). (C) The average Depression 
score for each of the five treatment groups after controlling for baseline. No significance 
was found. (D) The average Fatigue score for each of the five treatments groups for each 
visit after controlling for baseline. No significance was found. (E) The average Tension 
score for each of the five treatments groups for each visit after controlling for baseline. 
Significance was found between treatment groups (p < 0.05). (F) The average Vigor 
score for each of the five treatments groups for each visit after controlling for baseline. 








 The rapid growth of the older population of the United States’ and this 
population’s increasing health risks including obesity, chronic diseases, decreased quality 
of life, and premature death are expected to slow down anytime soon [1]. Determining 
the health risks associated with particular obesity levels has been shown to best be 
measured through BMI with waist measurements distinguishing health risks for a given 
BMI group [4]. The risk of obesity as well as poor sleep increases with age [22].  Poor 
sleep in turn, may lead to more emphasized signs of aging, obesity, and other hardships. 
Nutrition continues to be a key factor in preventing both muscle loss and body fat gain. 
Nutrition further emerges, as a preventative strategy to decrease sleep and mood 
dysregulation that comes with aging. Studies have shown that healthy aging is correlated 
with high O3FA consumption [10], as well as high protein diets via decreased body fat 
[11]. Guidelines for the promotion of healthy aging are needed. 
 Through this particular study, sleep, mood, BMI, waist circumference, and waist-
to-hip ratio measurements were all utilized in an attempt to determine the synergistic 
effect of protein and omega-3 fatty acid supplementation in a particular sector of the 
aging population—postmenopausal women. While the intervention lasted 16 weeks, 
improvements in any of the above measures were recognized as potential clues to nutrient 
supplementation’s effect on healthy aging.   
 Current literature suggests that poor sleep quality, as assessed by a variety of 
measures, is linked to low protein intake [7]. The findings of this study are aligned with 
this idea, as a major trend for the Protein + O3FA group to decrease in PSQI Global 
Score more than any other group from baseline to week 16. The significantly lowered 
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Global PSQI score from baseline to week 16 for the Protein + O3FA group as compared 
to the just O3FA group also aligns with the literature stating that increased intake of 
dietary protein has shown the ability to improve sleep quality as measured by Global 
PSQI scores [23]. High-protein diets have been found to improve sleep quality through 
decreasing the occurrence of wake episodes during sleep [7]. ActiGraph measurements 
for sleep quality did not align with the current literature for improved sleep with 
increased intake of dietary protein. The supplementation of protein did not show 
consistently clear improvement for these measures of sleep quality, but this could have 
due to small group sizes and the short duration of the intervention. 
Postmenopausal women’s sleep disturbances have been linked to mood symptoms 
in current literature, particularly depression and anxiety [16]. Current literature has 
presented the possibility of O3FAs to decrease depression [9]. POMS Depression scores 
trends aligned with the literature. The O3FA and Protein + O3FA groups both 
demonstrated the greatest trends in a decreased depression score from baseline to week 
16, showing an improved mood state with respect to the measurement of depression. In 
fact, the Protein + O3FA group both tended to trend toward a lower, improved mood 
score from baseline to week 16 for: TMD, Anger, Depression, Fatigue, and Tension. 
While BMI values did not display much improvement, both waist circumference 
and waist-to-hip ratios displayed a trend for all treatment groups, and not the control 
group, to demonstrate a decline from baseline to week 16. This is supported by the 
literature, as O3FA and protein consumption are known, individually, to decrease body 
fat [10, 11]. Postmenopausal women are afflicted by a great gain in waist circumference 
and waist-to-hip ratio when compared to their premenopausal counterparts [14]. Current 
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literature has found that dietary supplementation may aid to combat the fat gains 
experienced by postmenopausal women [10, 11]. The statistical significance found 
between treatment groups for waist-to-hip ratios, waist circumference, and the general 
trend shown in for all groups with dietary supplementation of whey protein and/or 
O3FAs to decline in waist-to-hip ratios and waist circumference measurements, aligns 
with the current literature.  
The effect of additional protein, O3FAs, and the combination of both protein and 
O3FA supplementation showed potential to counter the risks often associated with aging 
adult by promoting health aging. Protein and O3FAs appeared to positively impact the 
nutrition of aging adults and thus affect aging through improving various aspects of 
subjective sleep, mood, and anthropometric measurements.  
Limitations of this study included a small sample size, anthropometric human 
error, sleep diary human error, and subject compliance. Recruitment for human studies, 
combined with inclusion and exclusion criteria, is never an easy task. As the intervention 
was over the course of 16-weeks and included morning study day visits, total of 34 
participants fully completed the study. This sample size is not larger enough to be fully 
representative of the given population—aging United States’ postmenopausal women. 
Despite standardizing points to measuring waist circumferences, hip widths, and utilizing 
the same stadiometer and balance scales for all visits and participants, anthropometric 
human error during the course of the intervention could have occurred. The sleep diaries 
given to participants included instructions, but human error in recording proper times 
could have altered ActiGraph results when verifying the ActiGraph monitors with 
potentially incorrect sleep diaries. Finally, as the consumption of supplements—whether 
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whey protein, O3FA, or soybean oil placebo—was left to the participant on their own 
time in between visits, subject compliance cannot be fully verified. Subjects checked 
boxes as reminders for supplement consumption, returned empty supplement packaging, 
and were verbally asked their compliance from visit-to-visit, but this does not ensure 
correct compliance if perhaps a supplement dosage was mistakenly missed.  
Further study on the exact processes affected by protein and O3FAs in the aging 
adults’ body both individually and combined are needed. The epidemics of obesity, 
chronic diseases, and overall decreased quality of life currently impact many aging 
adults. This supports deeper inquiry into the bodily impact of nutrient supplementation. 
Postmenopausal women, in particular, tend to experience significant fat gain, highly 
report sleep disturbance, and are prone to mood disturbances at a higher rate compared to 
their male counterparts [15, 16, 17]. This study considered a demographic with much 
need for healthy aging guidelines that is overall underrepresented in research. Protein and 
O3FAs appear to have the potential to assist in achieving healthier aging, and more 
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